Navidea Biopharmaceuticals (NAVB) 10-Q 9 Nov 18 2018 Q3 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	9 Months Ended
	Sep. 30, 2018	Nov. 01, 2018
Document Information [Line Items]
Entity Registrant Name	NAVIDEA BIOPHARMACEUTICALS, INC.
Entity Central Index Key	810,509
Trading Symbol	navb
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Entity Current Reporting Status	Yes
Entity Emerging Growth Company	false
Entity Small Business	false
Entity Common Stock, Shares Outstanding (in shares)		181,890,700
Document Type	10-Q
Document Period End Date	Sep. 30, 2018
Document Fiscal Year Focus	2,018
Document Fiscal Period Focus	Q3
Amendment Flag	false

Consolidated Balance Sheets (Cu

Consolidated Balance Sheets (Current Period Unaudited) - USD ($)	Sep. 30, 2018	Dec. 31, 2017
Current assets:
Cash and cash equivalents	$ 5,707,465	$ 2,795,006
Available-for-sale securities	798,948	1,797,604
Accounts and other receivables	86,928	8,137,872
Prepaid expenses and other	547,027	1,101,923
Total current assets	7,140,368	13,832,405
Property and equipment	1,224,310	1,206,058
Less accumulated depreciation and amortization	1,059,132	969,357
Property and equipment, net	165,178	236,701
Patents, trademarks and license agreements	480,404	480,404
Less accumulated amortization	44,496	22,248
Patents, trademarks and license agreements, net	435,908	458,156
Guaranteed earnout receivable		4,809,376
Other assets	1,367,588	1,444,798
Total assets	9,109,042	20,781,436
Current liabilities:
Accounts payable	615,524	855,043
Accrued liabilities and other	2,950,140	1,857,848
Notes payable	2,164,330	2,353,639
Terminated lease liability, current	116,901	107,215
Accrued loss for CRG litigation		2,887,566
Liabilities associated with discontinued operations, current		7,092
Total current liabilities	5,846,895	8,068,403
Terminated lease liability	487,501	588,092
Deferred revenue	700,000	11,024
Other liabilities	64,583	65,587
Total liabilities	7,098,979	8,733,106
Commitments and contingencies (Note 11)
Stockholders’ equity:
Preferred stock; $.001 par value; 5,000,000 shares authorized; no shares issued or outstanding at September 30, 2018 and December 31, 2017
Common stock; $.001 par value; 300,000,000 shares authorized; 181,890,700 and 162,206,646 shares issued and outstanding at September 30, 2018 and December 31, 2017, respectively	181,891	162,207
Additional paid-in capital	334,723,420	331,128,787
Accumulated deficit	(333,562,563)	(319,908,968)
Accumulated other comprehensive loss	(1,052)	(2,396)
Total Navidea stockholders' equity	1,341,696	11,379,630
Noncontrolling interest	668,367	668,700
Total stockholders’ equity	2,010,063	12,048,330
Total liabilities and stockholders’ equity	$ 9,109,042	$ 20,781,436

Consolidated Balance Sheets (_2

Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares	Sep. 30, 2018	Dec. 31, 2017
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	5,000,000	5,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	300,000,000	300,000,000
Common stock, shares issued (in shares)	181,890,700	162,206,646
Common stock, shares outstanding (in shares)	181,890,700	162,206,646

Consolidated Statements of Oper

Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended			9 Months Ended
	Sep. 30, 2018		Sep. 30, 2017	Sep. 30, 2018		Sep. 30, 2017
Revenue:
Revenue from contract with customer	$ 22,000			$ 287,000
Grant and other revenue	209,146		$ 223,669	762,549		$ 1,315,298
Revenue	231,458		223,669	1,050,030		1,415,298
Cost of revenue	38,101			73,811
Gross profit	193,357		223,669	976,219		1,415,298
Operating expenses:
Research and development expenses	1,225,770		874,547	3,367,444		2,765,695
Selling, general and administrative	2,688,703		1,734,707	6,254,474		9,006,725
Total operating expenses	3,914,473		2,609,254	9,621,918		11,772,420
Loss from operations	(3,721,116)	[1]	(2,385,585)	(8,645,699)	[1]	(10,357,122)	[1]
Other (expense) income:
Interest (expense) income, net	(28,074)		76,050	(20,234)		144,811
Change in fair value of financial instruments						153,357
Loss on extinguishment of debt				(4,265,434)		(1,314,102)
Other, net	3,540		(6,979)	1,654		(45,256)
Total other (expense) income, net	(24,534)	[2]	69,071	(4,284,014)	[2]	(1,061,190)	[2]
Loss before income taxes	(3,745,650)		(2,316,514)	(12,929,713)		(11,418,312)
Income tax expense	(76,259)		775,750	(65,330)		3,861,156
Loss from continuing operations	(3,821,909)		(1,540,764)	(12,995,043)		(7,557,156)
Discontinued operations, net of tax effect:
(Loss) income from discontinued operations			5,399	(1,938)		(332,838)
Gain on sale			145,877	43,053		86,894,000
Net (loss) income	(3,821,909)		(1,389,488)	(12,953,928)		79,004,006
Less loss attributable to noncontrolling interest	(308)		(23)	(333)		(192)
Net (loss) income attributable to common stockholders	$ (3,821,601)		$ (1,389,465)	$ (12,953,595)		$ 79,004,198
(Loss) income per common share (basic):
Continuing operations (in dollars per share)	$ (0.02)		$ (0.01)	$ (0.08)		$ (0.05)
Discontinued operations (in dollars per share)						0.54
Attributable to common stockholders (in dollars per share)	$ (0.02)		$ (0.01)	$ (0.08)		$ 0.49
Weighted average shares outstanding (basic) (in shares)	166,855,420		162,006,646	163,963,940		161,437,276
(Loss) income per common share (diluted):
Continuing operations (in dollars per share)	$ (0.02)		$ (0.01)	$ (0.08)		$ (0.05)
Discontinued operations (in dollars per share)						0.52
Attributable to common stockholders (in dollars per share)	$ (0.02)		$ (0.01)	$ (0.08)		$ 0.47
Weighted average shares outstanding (diluted) (in shares)	166,855,420		162,006,646	163,963,940		165,914,473
Royalty [Member]
Revenue:
Revenue from contract with customer	$ 2,382			$ 9,842
License [Member]
Revenue:
Revenue from contract with customer	$ 19,930			$ 277,639		$ 100,000
[1]	Income (loss) from operations does not reflect the allocation of certain selling, general and administrative expenses, excluding depreciation and amortization, to our individual reportable segments, other than those expenses directly incurred by MT.
[2]	Amounts consist primarily of losses on debt extinguishment and changes in fair value of financial instruments, which are not currently allocated to our individual reportable segments.

Consolidated Statements of Comp

Consolidated Statements of Comprehensive (Loss) Income (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Net (loss) income	$ (3,821,909)	$ (1,389,488)	$ (12,953,928)	$ 79,004,006
Unrealized gain (loss) on available-for-sale securities	1,012	(172)	1,344	(1,200)
Comprehensive (loss) income	$ (3,820,897)	$ (1,389,660)	$ (12,952,584)	$ 79,002,806

Consolidated Statement of Stock

Consolidated Statement of Stockholders' Equity (Unaudited) - 9 months ended Sep. 30, 2018 - USD ($)	Private Placement [Member]Common Stock [Member]	Private Placement [Member]Additional Paid-in Capital [Member]	Private Placement [Member]Retained Earnings [Member]	Private Placement [Member]AOCI Attributable to Parent [Member]	Private Placement [Member]Noncontrolling Interest [Member]	Private Placement [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	AOCI Attributable to Parent [Member]	Noncontrolling Interest [Member]	Total
Balance (in shares) at Dec. 31, 2017							162,206,646
Balance at Dec. 31, 2017							$ 162,207	$ 331,128,787	$ (319,908,968)	$ (2,396)	$ 668,700	$ 12,048,330
Impact of adoption of ASC Topic 606 at Dec. 31, 2017									(700,000)			(700,000)
Issued stock in payment of employee bonuses (in shares)							1,118,760
Issued stock in payment of employee bonuses							$ 1,118	315,784				316,902
Issued restricted stock (in shares)							200,000
Issued restricted stock							$ 200					200
Cancelled forfeited restricted stock (in shares)							(50,000)
Cancelled forfeited restricted stock							$ (50)	50
Issued stock to 401(k) plan (in shares)							94,684					94,684
Issued stock to 401(k) plan							$ 95	35,885				$ 35,980
Issued stock pursuant to private placement (in shares)	18,320,610					18,320,610
Issued stock pursuant to private placement	$ 18,321	$ 2,981,679				$ 3,000,000
Stock compensation expense								261,235				261,235
Net loss									(12,953,595)		(333)	(12,953,928)
Unrealized gain on available-for-sale securities										1,344		1,344
Total comprehensive loss												(12,952,584)
Balance (in shares) at Sep. 30, 2018							181,890,700
Balance at Sep. 30, 2018							$ 181,891	$ 334,723,420	$ (333,562,563)	$ (1,052)	$ 668,367	$ 2,010,063

Consolidated Statements of Cash

Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017
Cash flows from operating activities:
Net (loss) income	$ (12,953,928)	$ 79,004,006
Adjustments to reconcile net (loss) income to net cash provided by operating activities:
Depreciation and amortization	113,088	212,077
Loss on disposal and abandonment of assets		806,710
Compounded interest on long term debt	128,902	211,443
Stock compensation expense	261,235	319,807
Change in fair value of financial instruments		(153,357)
Loss on extinguishment of debt	4,265,434	1,314,102
Issued warrants in connection with Asset Sale		3,337,187
Value of stock issued to directors		10,500
Value of stock issued to employees	316,902	369,342
Value of stock issued to 401(k) plan for employer matching contributions	35,980	53,707
Changes in operating assets and liabilities:
Accounts and other receivables	12,860,320	(12,686,071)
Inventory		1,470,826
Prepaid expenses and other assets	632,106	495,434
Accounts payable	(239,519)	(5,897,416)
Accrued and other liabilities	992,304	(5,507,487)
Deferred revenue	(10,037)	(2,315,037)
Net cash provided by operating activities	6,402,787	61,045,773
Cash flows from investing activities:
Purchases of available-for-sale securities	(200,000)	(2,200,000)
Proceeds from sales of available-for-sale securities	200,000
Maturities of available-for-sale securities	1,000,000	200,000
Purchases of equipment	(19,317)	(31,417)
Net cash provided by (used in) investing activities	980,683	(2,031,417)
Cash flows from financing activities:
Proceeds from issuance of common stock	3,000,200	54,319
Payment of debt-related costs	(7,153,000)	(1,314,102)
Principal payments on notes payable	(318,211)	(59,675,502)
Net cash used in financing activities	(4,471,011)	(60,935,285)
Net increase (decrease) in cash and cash equivalents	2,912,459	(1,920,929)
Cash and cash equivalents, beginning of period	2,795,006	6,540,578
Cash and cash equivalents, end of period	$ 5,707,465	$ 4,619,649

Note 1 - Summary of Significant

Note 1 - Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2018
Notes to Financial Statements
Significant Accounting Policies [Text Block]	1. Summary of Significant Accounting Policies a. Basis of Presentation: September 30, 2018 three nine September 30, 2018 2017 September 30, 2018 not December 31, 2017, 10 In March 2017, 414, 414” ® 3. 414, Tc99m Our consolidated financial statements include the accounts of Navidea and our wholly-owned subsidiaries, Navidea Biopharmaceuticals Limited and Cardiosonix Ltd, as well as those of our majority-owned subsidiary, Macrophage Therapeutics, Inc. (“MT”). All significant inter-company accounts were eliminated in consolidation. Cardiosonix was legally dissolved in September 2017. Our consolidated balance sheets and statements of operations have been reclassified, as required, for all periods presented to reflect the Business as a discontinued operation. Cash flows associated with the operation of the Business have been combined with operating, investing and financing cash flows, as appropriate, in our consolidated statements of cash flows. See Note 3. Certain prior period amounts also have been reclassified to conform to the current year’s presentation, including the adoption of Accounting Standards Update (“ASU”) No. 2014 09, Revenue from Contracts with Customers , b. Financial Instruments and Fair Value: ( 1 Cash, available-for-sale securities, accounts and other receivables, and accounts payable: September 30, 2018 December 31, 2017, $96,000 2016. ( 2 Notes payable: September 30, 2018 December 31, 2017 September 30, 2018, $2.2 $2.2 December 31, 2017, $2.4 $2.4 9. ( 3 Derivative liabilities: $63,000 September 30, 2018 December 31, 2017 September 30, 2018 December 31, 2017 5. ( 4 Warrants: March 2017, 414 five 10 1 $1.50 414 $3.3 nine September 30, 2017. $334,000, 13. c. Recently Adopted Accounting Standards: May 2014, 2014 09, Revenue from Contracts with Customers (Topic 606 2014 09 2014 09 five may 2014 09, 606 2014 09, 2016 08, 2016 10, 2016 12 2016 20, January 1, 2018, 2014 09 $700,000 4. In November 2016, No. 2016 18, Statement of Cash Flows – Restricted Cash 2016 18 2016 18 December 15, 2017, 2016 18 2016 18 January 1, 2018. 2016 18 $5.0 nine September 30, 2017. In March 2018, No. 2018 05, Income Taxes (Topic 740 – Amendments to SEC Paragraphs Pursuant to SEC Staff Accounting Bulletin No. 118 2018 05 740 No. 118. 2018 05 740 2018 05 March 2018 not d . Recent ly Issued A ccounting Standards: February 2016, No. 2016 02, Leases (Topic 842 2016 02 842 2016 02 December 15, 2018, 2016 02, fourth 2018. 2016 02 $300,000 In June 2018, No. 2018 07, Compensation—Stock Compensation (Topic 718 2018 07 718 718 2018 07 718 718 not 1 2 606, Revenue from Contracts with Customers 2018 07 December 15, 2018, 2018 07 not In July 2018, No. 2018 09, Codification Improvements 2018 09 2018 09 December 15, 2018 2018 09 not Also in July 2018, No. 2018 10, Codification Improvements to Topic 842, No. 2018 11, Targeted Improvements to Topic 842, 2018 10 842 2016 02, Leases (Topic 842 2018 11 840, Leases 840 840. 2018 10 2018 11 2016 02 December 15, 2018. not 2018 10 2018 11 In August 2018, No. 2018 13, Disclosure Framework—Changes to the Disclosure Requirements for Fair Value Measurement 2018 13 280, 2018 13 1 1 2 2 3 3 4 3 2018 13 1 3 3 3 2 3 2018 13 1 3 2 3 2018 13 December 15, 2019. not 2018 13 may

Note 2 - Liquidity

Note 2 - Liquidity	9 Months Ended
	Sep. 30, 2018
Notes to Financial Statements
Substantial Doubt about Going Concern [Text Block]	2. Liquidity As disclosed in the Company’s Annual Report on Form 10 $4.1 $1.9 October 31, 2018, 9 11. Effective August 14, 2018, one $978,000 two one $35,000 16 23.5 11. On September 13, 2018, 18,320,610 $3.0 12. The Company has experienced recent unfavorable court rulings and is currently still engaged in lawsuits with CRG. In addition, the Company has experienced recurring net losses and has used significant cash to fund its operations. Our projected cash burn factors in certain cost cutting initiatives that have been approved by the Board of Directors and implemented, including reductions in the workforce and a reduction in facilities expenses. Additionally, we have considerable discretion over the extent of development project expenditures and have the ability to curtail the related cash flows as needed. The Company also has funds remaining under outstanding grant awards, and continues working to establish new sources of funding, including collaborations, potential equity investments, and additional grant funding that can augment the balance sheet. However, based on our current working capital and our projected cash burn, and without definitive agreements in place for additional funding, management believes that there is substantial doubt about the Company’s ability to continue as a going concern for at least twelve 10

Note 3 - Discontinued Operation

Note 3 - Discontinued Operations	9 Months Ended
	Sep. 30, 2018
Notes to Financial Statements
Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]	3 . Discontinued Operations On March 3, 2017, November 23, 2016 ( 414 ® In exchange for the Acquired Assets, Cardinal Health 414 $80.6 $3.0 Upon closing of the Asset Sale, the Supply and Distribution Agreement dated November 15, 2007, 414 no On April 2, 2018, 414 $6.0 not $7.1 414 414 414 April 9, 2018, $7.1 $4.1 $59.0 We recorded a net gain on the sale of the Business of $86.9 nine September 30, 2017, $16.5 $3.3 414, $2.0 $800,000 $6.4 $43,000 nine September 30, 2018, $54,000 $11,000 As a result of the Asset Sale, we reclassified certain assets and liabilities as assets and liabilities associated with discontinued operations. The following liabilities have been segregated and included in liabilities associated with discontinued operations, as appropriate, in the consolidated balance sheets: September 30 , 2018 December 31, 2017 Accrued liabilities $ — $ 7,092 Liabilities associated with discontinued operations, current $ — $ 7,092 In addition, we reclassified certain revenues and expenses related to the Business to discontinued operations for all periods presented, including interest expense related to the CRG and Platinum debt obligations as required by current accounting guidance. The following amounts have been segregated from continuing operations and included in discontinued operations in the consolidated statements of operations: Three Months Ended September 30, Nine Months Ended September 30, 2018 2017 2018 2017 Lymphoseek sales revenue $ — $ — $ — $ 2,917,213 Cost of goods sold — — — 364,192 Gross profit — — — 2,553,021 Operating expenses: Research and development — (5,951 ) 2,453 382,070 Selling, general and administrative — — — 805,464 Total operating expenses — (5,951 ) 2,453 1,187,534 (Loss) income from discontinued operations — 5,951 (2,453 ) 1,365,487 Interest expense — — — (1,718,506 ) (Loss) income before income taxes — 5,951 (2,453 ) (353,019 ) Benefit from (provision for) income taxes — (552 ) 515 20,181 (Loss) income from discontinued operations $ — $ 5,399 $ (1,938 ) $ (332,838 )

Note 4 - Revenue From Contracts

Note 4 - Revenue From Contracts With Customers	9 Months Ended
	Sep. 30, 2018
Notes to Financial Statements
Revenue from Contract with Customer [Text Block]	4 . Revenue from Contracts with Customers The Company adopted ASU 2014 09, January 1, 2018, three nine September 30, 2018 January 1, 2018 not January 1, 2018. We earn revenues related to our licensing and distribution agreements. The terms of these agreements may The cumulative effect of the change on accumulated deficit as of January 1, 2018 $700,000, $100,000 Tc99m June 2017, $600,000 Tc99m August 2014. not Pre- Adoption Post- Adoption Change Deferred revenue $ 26,061 $ 726,061 $ 700,000 Accumulated deficit (319,908,968 ) (320,608,968 ) (700,000 ) During the three nine September 30, 2018, $22,000 $287,000, not Navidea is focused on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. We manage our business based on two Tc99m Tc99m one Tc99 In April 2018, NAV4694, NAV4694 The following tables disaggregate the Company’s revenue from contracts with customers for the three nine September 30, 2018. T hree Months Ended September 30 , 2018 Diagnostics Therapeutics Total Tc99m tilmanocept royalty revenue: Europe $ 2,382 $ — $ 2,382 India — — — China — — — Total $ 2,382 $ — $ 2,382 License revenue: NAV4694 sublicense $ 14,930 $ — $ 14,930 Tc99m tilmanocept sublicense, China 5,000 — 5,000 Total $ 19,930 $ — $ 19,930 Other revenue: Additional stability studies $ — $ — $ — Nine Months Ended Sep t ember 30, 2018 Diagnostics Therapeutics Total Tc99m tilmanocept royalty revenue: Europe $ 9,842 $ — $ 9,842 India — — — China — — — Total $ 9,842 $ — $ 9,842 License revenue: NAV4694 sublicense $ 272,639 $ — $ 272,639 Tc99m tilmanocept sublicense, China 5,000 — 5,000 Total $ 277,639 $ — $ 277,639 Other revenue: Additional stability studies $ 15,037 $ — $ 15,037 The following economic factors affect the nature, amount, timing and uncertainty of the Company’s revenue and cash flows as indicated: Geographical L ocation of C ustomers: may may Status of Regulatory Approval: Tc99m Tc99m not may The following table summarizes the changes in contract liabilities, the current portion of which is included in accrued liabilities and other in the consolidated balance sheets, during the three nine September 30, 2018 2017: Three Months Ended September 30, Nine Months Ended September 30, 2018 2017 2018 2017 Total deferred revenue, beginning of period $ 721,024 $ 26,061 $ 26,061 $ 41,098 Impact of adoption of ASU 2014-09 and related standards — — 700,000 — Revenue deferred related to sublicense — — 10,000 — Revenue recognized from satisfaction of performance obligations (5,000 ) — (20,037 ) (15,037 ) Total deferred revenue, end of period $ 716,024 $ 26,061 $ 716,024 $ 26,061 Currently, the Company recognizes revenue from up-front license fees and pre-market milestones after the cash has been received from its customers and the performance obligations have been met. Payments for sales-based royalties and milestones are generally received after the related revenue has been recognized and invoiced. Normal payment terms generally range from 15 90 $10,000 September 30, 2018. During the three nine September 30, 2018, not Up-front and milestone payments received related to our license and distribution agreements in India and China are deferred until Tc99m not Tc99m not no not eight 10 The transaction price of a contract is the amount of consideration to which the Company expects to be entitled in exchange for transferring promised goods or services to a customer. Transaction prices do not third not When estimating a contract’s transaction price, the Company considers all the information (historical, current, and forecasted) that is reasonably available to it and identifies possible consideration amounts. Most of the Company’s contracts with customers include both fixed and variable components of the transaction price. Under those contracts, some or all of the consideration for satisfied performance obligations is contingent on events over which the Company has no Tc99m The milestone payments have a binary outcome (that is, the Company will either receive all or none not Royalties are estimated based on the expected value method because they are based on a variable amount of sales representing a range of possible outcomes. However, when taking into account the constraint on variable consideration, the estimate of future royalties included in the transaction price is generally $0. Tc99m not no no The sublicense of NAV4694 Up-front fees, milestones and royalties are generally non-refundable. Therefore, the Company does not Through September 30, 2018, not

Note 5 - Fair Value

Note 5 - Fair Value	9 Months Ended
	Sep. 30, 2018
Notes to Financial Statements
Fair Value Disclosures [Text Block]	5. Fair Value MT issued warrants to purchase MT Common Stock with certain characteristics including a net settlement provision that require the warrants to be accounted for as a derivative liability at fair value on the consolidated balance sheets. The estimated fair value of the MT warrants is $63,000 September 30, 2018 December 31, 2017, 1 The following table sets forth, by level, financial liabilities measured at fair value on a recurring basis: Liabilities Measured at Fair Value on a Recurri ng Basis as of September 30, 2018 and December 31, 2017 Description Quoted Prices in Active Markets for Identical Liabilities (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Total Liability related to MT warrants $ — $ — $ 63,000 $ 63,000 a. Valuation Processes-Level 3 third b. Sensitivity Analysis-Level 3 may may not There were no 1 2 three nine September 30, 2018 2017. no 1 2 three nine September 30, 2018 2017. 3 3 three September 30, 2018 2017 $0 3 nine September 30, 2018 2017 $0 $153,000,

Note 6 - Stock-based Compensati

Note 6 - Stock-based Compensation	9 Months Ended
	Sep. 30, 2018
Notes to Financial Statements
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	6 . Stock-Based Compensation For the three September 30, 2018 2017, $44,000 $64,000, nine September 30, 2018 2017, $261,000 $320,000, not three nine September 30, 2018 2017. A summary of the status of our stock options as of September 30, 2018, nine Nine Months Ended September 30, 2018 Number of Options Weighted Average Exercise Price Weighted Average Remaining Contractual Life (in years) Aggregate Intrinsic Value Outstanding at beginning of period 3,687,679 $ 1.50 Granted 470,000 0.53 Exercised — — Canceled and Forfeited (116,000 ) 0.71 Expired (7,000 ) 0.66 Outstanding at end of period 4,034,679 $ 1.41 6.3 $ — Exercisable at end of period 2,260,683 $ 2.00 4.3 $ — A summary of the status of our unvested restricted stock as of September 30, 2018, nine Nine Months Ended September 30, 2018 Number of Shares Weighted Average Grant-Date Fair Value Unvested at beginning of period 150,000 $ 0.51 Granted 200,000 0.37 Vested (200,000 ) 0.47 Forfeited (50,000 ) 0.36 Unvested at end of period 100,000 $ 0.37 As of September 30, 2018, $101,000 1.2

Note 7 - (Loss) Earnings Per Sh

Note 7 - (Loss) Earnings Per Share	9 Months Ended
	Sep. 30, 2018
Notes to Financial Statements
Earnings Per Share [Text Block]	7 . (Loss) Earnings Per Share Basic (loss) earnings per share is calculated by dividing net (loss) income attributable to common stockholders by the weighted-average number of common shares and, except for periods with a loss from operations, participating securities outstanding during the period. Diluted (loss) earnings per share reflects additional common shares that would have been outstanding if dilutive potential common shares had been issued. Potential common shares that may The following table sets forth the reconciliation of the weighted average number of common shares outstanding used to compute basic and diluted (loss) earnings per share for the three nine September 30, 2018 2017: Three Months Ended September 30, Nine Months Ended September 30, 2018 2017 2018 2017 Weighted average shares outstanding, basic 166,855,420 162,006,646 163,963,940 161,437,276 Dilutive shares related to warrants — — — 4,277,197 Unvested restricted stock — — — 200,000 Weighted average shares outstanding, diluted 166,855,420 162,006,646 163,963,940 165,914,473 Diluted (loss) earnings per common share for the nine September 30, 2018 2017 18.6 15.1 The Company’s unvested stock awards contain nonforfeitable rights to dividends or dividend equivalents, whether paid or unpaid (referred to as “participating securities”). Therefore, the unvested stock awards are required to be included in the number of shares outstanding for both basic and diluted earnings per share calculations. However, due to our loss from continuing operations, 100,000 200,000 nine September 30, 2018 2017,

Note 8 - Accounts Payable, Accr

Note 8 - Accounts Payable, Accrued Liabilities and Other	9 Months Ended
	Sep. 30, 2018
Notes to Financial Statements
Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]	8. Accounts Payable, Accrued Liabilities and Other At September 30, 2018, $96,000 2016. Accrued liabilities and other at September 30, 2018 December 31, 2017 $2.3 $975,000,

Note 9 - Notes Payable

Note 9 - Notes Payable	9 Months Ended
	Sep. 30, 2018
Notes to Financial Statements
Debt Disclosure [Text Block]	9 . Notes Payable Platinum -Montaur Life Sciences LLC In July 2012, $50 414, $7.7 11. During the nine September 30, 2018 2017, $129,000 $211,000 nine September 30, 2017, $143,000 September 30, 2018, $2.2 The Platinum Note is reflected on the consolidated balance sheets at its estimated fair value, which includes the estimated fair value of the embedded conversion option of $0 September 30, 2018 December 31, 2017. $0 three September 30, 2018 2017. $0 $153,000, nine September 30, 2018 2017. $2.2 $2.0 September 30, 2018 December 31, 2017, Capital Royalty Partners II, L.P. In May 2015, $50.0 March 3, 2017, 414. March 3, 2017, $59.0 As disclosed in the Company’s Annual Report on Form 10 December 2017, $66.0 $66.0 $59.0 March 2017, $7.0 not June 2016 $4.1 $66.0 $4.1 April 2018, $7.1 $4.1 $59.0 $4.1 $7.0 $4.1 11. IPFS Corporation In December 2016, $348,000 8.99%. eight $45,000, July 2017. In November 2017, $396,000 4.0%. ten $40,000, August 2018. $0 $318,000 September 30, 2018 December 31, 2017, Summary During the three September 30, 2018 2017, $45,000 $26,000, $44,000 $29,000 three September 30, 2018 2017, nine September 30, 2018 2017, $134,000 $91,000, $129,000 $68,000 nine September 30, 2018 2017,

Note 10 - Terminated Lease Liab

Note 10 - Terminated Lease Liability	9 Months Ended
	Sep. 30, 2018
Notes to Financial Statements
Terminated Lease Liability Disclosure [Text Block]	10. Terminated Lease Liability Effective June 1, 2017, 5600 4995 no October 2022. In accordance with current accounting guidance, the Company initially recorded a total liability of $1.0 $399,000 $706,000. December 31, 2017. A summary of the changes in our terminated lease liability during the nine September 30, 2018 Terminated Lease Liability Total liability, January 1, 2018 $ 695,307 Changes in estimated future payments (43,393 ) Payments under Blazer lease (349,290 ) Receipts from subtenant 273,869 Accretion of liability 27,909 Total liability, September 30, 2018 $ 604,402

Note 11 - Commitments and Conti

Note 11 - Commitments and Contingencies	9 Months Ended
	Sep. 30, 2018
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	1 1 . Commitments and Contingencies We are subject to legal proceedings and claims that arise in the ordinary course of business. Sinotau Litigation – NAV4694 On August 31, 2015, NAV4694 September 2016, In October 2017, NAV4694, NAV4694 not In April 2018, NAV4694, NAV4694 September 2018. CRG Litigation As disclosed in the Company’s Annual Report on Form 10 December 2017, $66.0 $66.0 2017. $59.0 March 2017, $7.0 not June 2016 $4.1 $66.0 $4.1 $4.1 $7.0 On January 16, 2018, $66.0 $4.1 June 2016, $2.9 March 26, 2018, $7.7 April 2, 2018, $4.1 June 2016 $66.0 October 1, 2018 October 31, 2018. November 20, 2018. not 2019 On April 9, 2018, $7.1 $4.1 $59.0 On April 12, 2018 2017, $66.0 $66.0 $4.1 June 2016 $66.0 $66.0 $7.1 414 May 22, 2018 June 26, 2018 August 16, 2018, $4.1million August 27, 2018, 2019. In a related proceeding before the Ohio Court, initially filed in 2016, 2017, $66.0 not $4.1 $4.1 On April 11, 2018, not $7.1 414 April 16, 2018, April 27, 2018. August 17, 2018, October 23, 2018 November 12, 2018. not 2019 On July 11, 2018, first not 2 9. Sinotau Litigation – Tc99m Tilmanocept On February 1, 2017, Tc99m 414. February 3, 2017, March 6, 2017. March 3, 2017. March 6, 414 February 2, 2017. July 12, 2017, July 27, 2017 60 February 8, 2018, February 17, 2018, February 20, 2018, Platinum-Montaur Litigation On November 2, 2017, $1.9 March 3, 2017, December 6, 2017. January 26, 2018 March 9, 2018, April 6, 2018. October 31, 2018, no Goldberg Agreement Effective August 14, 2018, one $978,000 two one $35,000 16 23.5 23.5 18 5% As of the date of filing this Quarterly Report on Form 10 not None 23.5 NYSE American Continued Listing Standards On August 14, 2018, not not 1003 $4.0 three four $2.1 June 30, 2018, four five December 31, 2017. Navidea was required to submit a plan to the NYSE American by September 14, 2018 February 14, 2020. On October 25, 2018, not 1003 $6.0 five $2.1 June 30, 2018, five December 31, 2017. The Company must provide quarterly updates to the NYSE American staff (the “Staff”) concurrent with its interim/annual SEC filings. If Navidea fails to regain compliance with the stockholders’ equity standards by February 14, 2020, may In addition, the Deficiency Letter stated that the Staff determined that the Company’s securities have been selling for a low price per share for a substantial period of time and, pursuant to Section 1003 $0.001 no February 14, 2019. February 14, 2020. In accordance with ASC Topic 450, Contingencies not

Note 12 - Equity Instruments

Note 12 - Equity Instruments	9 Months Ended
	Sep. 30, 2018
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	12 . Equity Instruments During September 2018, 18,320,610 $0.001 $3.0 During the nine September 30, 2018 2017, 1,118,760 710,353 $317,000 $369,000, 2017, 2016 2015 During the nine September 30, 2018 2017, 94,684 105,308 401 $36,000 $54,000, During the nine September 30, 2017, 16,406 $10,500 not nine September 30, 2018.

Note 13 - Stock Warrants

Note 13 - Stock Warrants	9 Months Ended
	Sep. 30, 2018
Notes to Financial Statements
Stock Warrants Disclosure [Text Block]	1 3 . Stock Warrants In January 2017, 5,411,850 5,411,850 $54,119. In March 2017, 414 five 10 1 $1.50 five 77% five 2%. 414 $3.3 nine September 30, 2017. $334,000, nine September 30, 2017. At September 30, 2018, 16.4 $0.01 $2.50 $1.15 one 17 In addition, at September 30, 2018, 300 $2,000

Note 14 - Income Taxes

Note 14 - Income Taxes	9 Months Ended
	Sep. 30, 2018
Notes to Financial Statements
Income Tax Disclosure [Text Block]	14. Income Taxes Income taxes are accounted for under the asset and liability method. Deferred tax assets (“DTAs”) and deferred tax liabilities (“DTLs”) are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases, and operating loss and tax credit carryforwards. DTAs and DTLs are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on DTAs and DTLs of a change in tax rates is recognized in income in the period that includes the enactment date. Current accounting standards require a valuation allowance against DTAs if, based on the weight of available evidence, it is more likely than not may not September 30, 2018 December 31, 2017, In assessing the realizability of DTAs, management considers whether it is more likely than not not not not September 30, 2018 The Tax Cuts and Jobs Act (the “Tax Act”) was signed into law on December 22, 2017. 35% 21%, January 1, 2018. 2018, 2019 2020. may 2018 2020, 50 2018, 2019 2020 2021. 6.2%, $76,000 nine September 30, 2018. $1.1 $1.2 September 30, 2018 December 31, 2017, may Current accounting standards include guidance on the accounting for uncertainty in income taxes recognized in the financial statements. Such standards also prescribe a recognition threshold and measurement model for the financial statement recognition of a tax position taken, or expected to be taken, and provides guidance on derecognition, classification, interest and penalties, accounting in interim periods, disclosure and transition. The Company believes that the ultimate deductibility of all tax positions is highly certain, although there is uncertainty about the timing of such deductibility. As a result, no September 30, 2018 December 31, 2017 not twelve September 30, 2018, 2014 2017 Provision for income taxes was $76,000 three September 30, 2018, 2.0%. $776,000 three September 30, 2017, 34.0%. three September 30, 2018 2017 As of September 30, 2018, $131.8 $20.4 $9.7

Note 15 - Segments

Note 15 - Segments	9 Months Ended
	Sep. 30, 2018
Notes to Financial Statements
Segment Reporting Disclosure [Text Block]	1 5 . Segments We report information about our operating segments using the “management approach” in accordance with current accounting standards. This information is based on the way management organizes and reports the segments within the enterprise for making operating decisions and assessing performance. Our reportable segments are identified based on differences in products, services and markets served. There were no two Tc99m NAV4694 April 2018), The information in the following tables is derived directly from each reportable segment’s financial reporting. T hree Months Ended September 30, 2018 Diagnostics Therapeutics Corporate Total Royalty revenue $ 2,382 $ — $ — $ 2,382 License revenue 19,930 — — 19,930 Grant and other revenue 65,505 143,641 — 209,146 Total revenue 87,817 143,641 — 231,458 Cost of revenue 38,101 — — 38,101 Research and development expenses 711,355 514,415 — 1,225,770 Selling, general and administrative expenses, excluding depreciation and amortization (1) — 20,532 2,630,581 2,651,113 Depreciation and amortization (2) — — 37,590 37,590 Loss from operations (3) (661,639 ) (391,306 ) (2,668,171 ) (3,721,116 ) Other expense (4) — — (24,534 ) (24,534 ) Income tax expense (10,081 ) (3,879 ) (62,299 ) (76,259 ) Net loss from continuing operations (671,720 ) (395,185 ) (2,755,004 ) (3,821,909 ) Net loss (671,720 ) (395,185 ) (2,755,004 ) (3,821,909 ) Total assets, net of depreciation and amortization: United States $ 117,722 $ 72,622 $ 8,899,301 $ 9,089,645 International 18,239 — 1,158 19,397 Capital expenditures — — 16,152 16,152 T hree Months Ended September 30, 2017 Diagnostics Therapeutics Corporate Total Grant and other revenue $ 210,479 $ 13,190 $ — $ 223,669 Research and development expenses 734,539 140,008 — 874,547 Selling, general and administrative expenses, excluding depreciation and amortization (1) — 13,359 1,671,022 1,684,381 Depreciation and amortization (2) — — 50,326 50,326 Loss from operations (3) (524,060 ) (140,177 ) (1,721,348 ) (2,385,585 ) Other income — — 69,071 69,071 Income tax benefit 175,496 46,942 553,312 775,750 Net loss from continuing operations (348,564 ) (93,235 ) (1,098,965 ) (1,540,764 ) Income from discontinued operations, net of tax 5,399 — — 5,399 Gain on sale of discontinued operations, net of tax 145,877 — — 145,877 Net loss (197,288 ) (93,235 ) (1,098,965 ) (1,389,488 ) Total assets, net of depreciation and amortization: United States $ 14,675,489 $ 10,591 $ 7,835,426 $ 22,521,506 International 82,334 — 1,867 84,201 Capital expenditures — — 23,247 23,247 Nine Months Ended September 30, 2018 Diagnostics Therapeutics Corporate Total Royalty revenue $ 9,842 $ — $ — $ 9,842 License revenue 277,639 — — 277,639 Grant and other revenue 454,830 307,719 — 762,549 Total revenue 742,311 307,719 — 1,050,030 Cost of revenue 73,811 — — 73,811 Research and development expenses 2,409,524 957,920 — 3,367,444 Selling, general and administrative expenses, excluding depreciation and amortization (1) — 45,769 6,095,617 6,141,386 Depreciation and amortization (2) — — 113,088 113,088 Loss from operations (3) (1,741,024 ) (695,970 ) (6,208,705 ) (8,645,699 ) Other expense (4) — — (4,284,014 ) (4,284,014 ) Income tax expense (8,797 ) (3,517 ) (53,017 ) (65,330 ) Net loss from continuing operations (1,749,821 ) (699,487 ) (10,545,736 ) (12,995,043 ) Loss from discontinued operations, net of tax (1,938 ) — — (1,938 ) Gain on sale of discontinued operations, net of tax 43,053 — — 43,053 Net loss (1,708,706 ) (699,487 ) (10,545,736 ) (12,953,928 ) Total assets, net of depreciation and amortization: United States $ 117,722 $ 72,622 $ 8,899,301 $ 9,089,645 International 18,239 — 1,158 19,397 Capital expenditures — — 19,317 19,317 Nine Months Ended September 30, 2017 Diagnostics Therapeutics Corporate Total License revenue $ 100,000 $ — $ — $ 100,000 Grant and other revenue 1,200,216 115,082 — 1,315,298 Total revenue 1,300,216 115,082 — 1,415,298 Research and development expenses 2,255,842 509,853 — 2,765,695 Selling, general and administrative expenses, excluding depreciation and amortization (1) — 19,342 8,789,728 8,809,070 Depreciation and amortization (2) — — 197,655 197,655 Loss from operations (3) (955,626 ) (414,113 ) (8,987,383 ) (10,357,122 ) Other expense (4) — — (1,061,190 ) (1,061,190 ) Income tax benefit 323,149 140,034 3,397,972 3,861,156 Net loss from continuing operations (632,477 ) (274,079 ) (6,650,601 ) (7,557,156 ) Loss from discontinued operations, net of tax (332,838 ) — — (332,838 ) Gain on sale of discontinued operations, net of tax 86,894,000 — — 86,894,000 Net income (loss) 85,928,685 (274,079 ) (6,650,601 ) 79,004,006 Total assets, net of depreciation and amortization: United States $ 14,675,489 $ 10,591 $ 7,835,426 $ 22,521,506 International 82,334 — 1,867 84,201 Capital expenditures — — 31,417 31,417 ( 1 General and administrative expenses, excluding depreciation and amortization, represent costs that relate to the general administration of the Company and as such are not ( 2 ) Depreciation and amortization is reflected in selling, general and administrative expenses ( $37,590 $50,326 three September 30, 2018 2017, $113,088 $197,655 nine September 30, 2018 2017, ( 3 ) Income (loss) from operations does not ( 4 ) Amounts consist primarily of losses on debt extinguishment and changes in fair value of financial instruments, which are not

Note 16 - Supplemental Disclosu

Note 16 - Supplemental Disclosure for Statements of Cash Flows	9 Months Ended
	Sep. 30, 2018
Notes to Financial Statements
Cash Flow, Supplemental Disclosures [Text Block]	16. Supplemental Disclosure for Statements of Cash Flows During the nine September 30, 2018 2017, $8,000 $7.4 nine September 30, 2018 2017, 94,684 105,308 401 $36,000 $54,000, nine September 30, 2017, 1.0 $334,000.

Note 17 - Subsequent Events

Note 17 - Subsequent Events	9 Months Ended
	Sep. 30, 2018
Notes to Financial Statements
Subsequent Events [Text Block]	1 7 . Subsequent Events The Company has evaluated events and transactions subsequent to September 30, 2018 10

Significant Accounting Policies

Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2018
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	a. Basis of Presentation: September 30, 2018 three nine September 30, 2018 2017 September 30, 2018 not December 31, 2017, 10 In March 2017, 414, 414” ® 3. 414, Tc99m Our consolidated financial statements include the accounts of Navidea and our wholly-owned subsidiaries, Navidea Biopharmaceuticals Limited and Cardiosonix Ltd, as well as those of our majority-owned subsidiary, Macrophage Therapeutics, Inc. (“MT”). All significant inter-company accounts were eliminated in consolidation. Cardiosonix was legally dissolved in September 2017. Our consolidated balance sheets and statements of operations have been reclassified, as required, for all periods presented to reflect the Business as a discontinued operation. Cash flows associated with the operation of the Business have been combined with operating, investing and financing cash flows, as appropriate, in our consolidated statements of cash flows. See Note 3. Certain prior period amounts also have been reclassified to conform to the current year’s presentation, including the adoption of Accounting Standards Update (“ASU”) No. 2014 09, Revenue from Contracts with Customers ,
Fair Value of Financial Instruments, Policy [Policy Text Block]	b. Financial Instruments and Fair Value: ( 1 Cash, available-for-sale securities, accounts and other receivables, and accounts payable: September 30, 2018 December 31, 2017, $ 96,000 2016. ( 2 Notes payable: September 30, 2018 December 31, 2017 September 30, 2018, $2.2 $2.2 December 31, 2017, $2.4 $2.4 9. ( 3 Derivative liabilities: $ 63,000 September 30, 2018 December 31, 2017 September 30, 2018 December 31, 2017 5. ( 4 Warrants: March 2017, 414 five 10 1 $1.50 414 $3.3 nine September 30, 2017. $334,000, 13.
New Accounting Pronouncements, Policy [Policy Text Block]	c. Recently Adopted Accounting Standards: May 2014, 2014 09, Revenue from Contracts with Customers (Topic 606 2014 09 2014 09 five may 2014 09, 606 2014 09, 2016 08, 2016 10, 2016 12 2016 20, January 1, 2018, 2014 09 $ 700,000 4. In November 2016, No. 2016 18, Statement of Cash Flows – Restricted Cash 2016 18 2016 18 December 15, 2017, 2016 18 2016 18 January 1, 2018. 2016 18 $5.0 nine September 30, 2017. In March 2018, No. 2018 05, Income Taxes (Topic 740 – Amendments to SEC Paragraphs Pursuant to SEC Staff Accounting Bulletin No. 118 2018 05 740 No. 118. 2018 05 740 2018 05 March 2018 not d . Recent ly Issued A ccounting Standards: February 2016, No. 2016 02, Leases (Topic 842 2016 02 842 2016 02 December 15, 2018, 2016 02, fourth 2018. 2016 02 $ 300,000 In June 2018, No. 2018 07, Compensation—Stock Compensation (Topic 718 2018 07 718 718 2018 07 718 718 not 1 2 606, Revenue from Contracts with Customers 2018 07 December 15, 2018, 2018 07 not In July 2018, No. 2018 09, Codification Improvements 2018 09 2018 09 December 15, 2018 2018 09 not Also in July 2018, No. 2018 10, Codification Improvements to Topic 842, No. 2018 11, Targeted Improvements to Topic 842, 2018 10 842 2016 02, Leases (Topic 842 2018 11 840, Leases 840 840. 2018 10 2018 11 2016 02 December 15, 2018. not 2018 10 2018 11 In August 2018, No. 2018 13, Disclosure Framework—Changes to the Disclosure Requirements for Fair Value Measurement 2018 13 280, 2018 13 1 1 2 2 3 3 4 3 2018 13 1 3 3 3 2 3 2018 13 1 3 2 3 2018 13 December 15, 2019. not 2018 13 may

Note 3 - Discontinued Operati_2

Note 3 - Discontinued Operations (Tables)	9 Months Ended
	Sep. 30, 2018
Notes Tables
Disposal Groups, Including Discontinued Operations [Table Text Block]	September 30 , 2018 December 31, 2017 Accrued liabilities $ — $ 7,092 Liabilities associated with discontinued operations, current $ — $ 7,092 Three Months Ended September 30, Nine Months Ended September 30, 2018 2017 2018 2017 Lymphoseek sales revenue $ — $ — $ — $ 2,917,213 Cost of goods sold — — — 364,192 Gross profit — — — 2,553,021 Operating expenses: Research and development — (5,951 ) 2,453 382,070 Selling, general and administrative — — — 805,464 Total operating expenses — (5,951 ) 2,453 1,187,534 (Loss) income from discontinued operations — 5,951 (2,453 ) 1,365,487 Interest expense — — — (1,718,506 ) (Loss) income before income taxes — 5,951 (2,453 ) (353,019 ) Benefit from (provision for) income taxes — (552 ) 515 20,181 (Loss) income from discontinued operations $ — $ 5,399 $ (1,938 ) $ (332,838 )

Note 4 - Revenue From Contrac_2

Note 4 - Revenue From Contracts With Customers (Tables)	9 Months Ended
	Sep. 30, 2018
Notes Tables
Disaggregation of Revenue [Table Text Block]	T hree Months Ended September 30 , 2018 Diagnostics Therapeutics Total Tc99m tilmanocept royalty revenue: Europe $ 2,382 $ — $ 2,382 India — — — China — — — Total $ 2,382 $ — $ 2,382 License revenue: NAV4694 sublicense $ 14,930 $ — $ 14,930 Tc99m tilmanocept sublicense, China 5,000 — 5,000 Total $ 19,930 $ — $ 19,930 Other revenue: Additional stability studies $ — $ — $ — Nine Months Ended Sep t ember 30, 2018 Diagnostics Therapeutics Total Tc99m tilmanocept royalty revenue: Europe $ 9,842 $ — $ 9,842 India — — — China — — — Total $ 9,842 $ — $ 9,842 License revenue: NAV4694 sublicense $ 272,639 $ — $ 272,639 Tc99m tilmanocept sublicense, China 5,000 — 5,000 Total $ 277,639 $ — $ 277,639 Other revenue: Additional stability studies $ 15,037 $ — $ 15,037
Contract with Customer, Asset and Liability [Table Text Block]	Three Months Ended September 30, Nine Months Ended September 30, 2018 2017 2018 2017 Total deferred revenue, beginning of period $ 721,024 $ 26,061 $ 26,061 $ 41,098 Impact of adoption of ASU 2014-09 and related standards — — 700,000 — Revenue deferred related to sublicense — — 10,000 — Revenue recognized from satisfaction of performance obligations (5,000 ) — (20,037 ) (15,037 ) Total deferred revenue, end of period $ 716,024 $ 26,061 $ 716,024 $ 26,061
Accounting Standards Update 2014-09 [Member]
Notes Tables
Schedule of New Accounting Pronouncements and Changes in Accounting Principles [Table Text Block]	Pre- Adoption Post- Adoption Change Deferred revenue $ 26,061 $ 726,061 $ 700,000 Accumulated deficit (319,908,968 ) (320,608,968 ) (700,000 )

Note 5 - Fair Value (Tables)

Note 5 - Fair Value (Tables)	9 Months Ended
	Sep. 30, 2018
Notes Tables
Fair Value, Liabilities Measured on Recurring Basis [Table Text Block]	Liabilities Measured at Fair Value on a Recurri ng Basis as of September 30, 2018 and December 31, 2017 Description Quoted Prices in Active Markets for Identical Liabilities (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Total Liability related to MT warrants $ — $ — $ 63,000 $ 63,000

Note 6 - Stock-based Compensa_2

Note 6 - Stock-based Compensation (Tables)	9 Months Ended
	Sep. 30, 2018
Notes Tables
Share-based Compensation, Stock Options, Activity [Table Text Block]	Nine Months Ended September 30, 2018 Number of Options Weighted Average Exercise Price Weighted Average Remaining Contractual Life (in years) Aggregate Intrinsic Value Outstanding at beginning of period 3,687,679 $ 1.50 Granted 470,000 0.53 Exercised — — Canceled and Forfeited (116,000 ) 0.71 Expired (7,000 ) 0.66 Outstanding at end of period 4,034,679 $ 1.41 6.3 $ — Exercisable at end of period 2,260,683 $ 2.00 4.3 $ —
Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]	Nine Months Ended September 30, 2018 Number of Shares Weighted Average Grant-Date Fair Value Unvested at beginning of period 150,000 $ 0.51 Granted 200,000 0.37 Vested (200,000 ) 0.47 Forfeited (50,000 ) 0.36 Unvested at end of period 100,000 $ 0.37

Note 7 - (Loss) Earnings Per _2

Note 7 - (Loss) Earnings Per Share (Tables)	9 Months Ended
	Sep. 30, 2018
Notes Tables
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	Three Months Ended September 30, Nine Months Ended September 30, 2018 2017 2018 2017 Weighted average shares outstanding, basic 166,855,420 162,006,646 163,963,940 161,437,276 Dilutive shares related to warrants — — — 4,277,197 Unvested restricted stock — — — 200,000 Weighted average shares outstanding, diluted 166,855,420 162,006,646 163,963,940 165,914,473

Note 10 - Terminated Lease Li_2

Note 10 - Terminated Lease Liability (Tables)	9 Months Ended
	Sep. 30, 2018
Notes Tables
Terminated Lease Liability [Table Text Block]	Terminated Lease Liability Total liability, January 1, 2018 $ 695,307 Changes in estimated future payments (43,393 ) Payments under Blazer lease (349,290 ) Receipts from subtenant 273,869 Accretion of liability 27,909 Total liability, September 30, 2018 $ 604,402

Note 15 - Segments (Tables)

Note 15 - Segments (Tables)	9 Months Ended
	Sep. 30, 2018
Notes Tables
Schedule of Segment Reporting Information, by Segment [Table Text Block]	T hree Months Ended September 30, 2018 Diagnostics Therapeutics Corporate Total Royalty revenue $ 2,382 $ — $ — $ 2,382 License revenue 19,930 — — 19,930 Grant and other revenue 65,505 143,641 — 209,146 Total revenue 87,817 143,641 — 231,458 Cost of revenue 38,101 — — 38,101 Research and development expenses 711,355 514,415 — 1,225,770 Selling, general and administrative expenses, excluding depreciation and amortization (1) — 20,532 2,630,581 2,651,113 Depreciation and amortization (2) — — 37,590 37,590 Loss from operations (3) (661,639 ) (391,306 ) (2,668,171 ) (3,721,116 ) Other expense (4) — — (24,534 ) (24,534 ) Income tax expense (10,081 ) (3,879 ) (62,299 ) (76,259 ) Net loss from continuing operations (671,720 ) (395,185 ) (2,755,004 ) (3,821,909 ) Net loss (671,720 ) (395,185 ) (2,755,004 ) (3,821,909 ) Total assets, net of depreciation and amortization: United States $ 117,722 $ 72,622 $ 8,899,301 $ 9,089,645 International 18,239 — 1,158 19,397 Capital expenditures — — 16,152 16,152 T hree Months Ended September 30, 2017 Diagnostics Therapeutics Corporate Total Grant and other revenue $ 210,479 $ 13,190 $ — $ 223,669 Research and development expenses 734,539 140,008 — 874,547 Selling, general and administrative expenses, excluding depreciation and amortization (1) — 13,359 1,671,022 1,684,381 Depreciation and amortization (2) — — 50,326 50,326 Loss from operations (3) (524,060 ) (140,177 ) (1,721,348 ) (2,385,585 ) Other income — — 69,071 69,071 Income tax benefit 175,496 46,942 553,312 775,750 Net loss from continuing operations (348,564 ) (93,235 ) (1,098,965 ) (1,540,764 ) Income from discontinued operations, net of tax 5,399 — — 5,399 Gain on sale of discontinued operations, net of tax 145,877 — — 145,877 Net loss (197,288 ) (93,235 ) (1,098,965 ) (1,389,488 ) Total assets, net of depreciation and amortization: United States $ 14,675,489 $ 10,591 $ 7,835,426 $ 22,521,506 International 82,334 — 1,867 84,201 Capital expenditures — — 23,247 23,247 Nine Months Ended September 30, 2018 Diagnostics Therapeutics Corporate Total Royalty revenue $ 9,842 $ — $ — $ 9,842 License revenue 277,639 — — 277,639 Grant and other revenue 454,830 307,719 — 762,549 Total revenue 742,311 307,719 — 1,050,030 Cost of revenue 73,811 — — 73,811 Research and development expenses 2,409,524 957,920 — 3,367,444 Selling, general and administrative expenses, excluding depreciation and amortization (1) — 45,769 6,095,617 6,141,386 Depreciation and amortization (2) — — 113,088 113,088 Loss from operations (3) (1,741,024 ) (695,970 ) (6,208,705 ) (8,645,699 ) Other expense (4) — — (4,284,014 ) (4,284,014 ) Income tax expense (8,797 ) (3,517 ) (53,017 ) (65,330 ) Net loss from continuing operations (1,749,821 ) (699,487 ) (10,545,736 ) (12,995,043 ) Loss from discontinued operations, net of tax (1,938 ) — — (1,938 ) Gain on sale of discontinued operations, net of tax 43,053 — — 43,053 Net loss (1,708,706 ) (699,487 ) (10,545,736 ) (12,953,928 ) Total assets, net of depreciation and amortization: United States $ 117,722 $ 72,622 $ 8,899,301 $ 9,089,645 International 18,239 — 1,158 19,397 Capital expenditures — — 19,317 19,317 Nine Months Ended September 30, 2017 Diagnostics Therapeutics Corporate Total License revenue $ 100,000 $ — $ — $ 100,000 Grant and other revenue 1,200,216 115,082 — 1,315,298 Total revenue 1,300,216 115,082 — 1,415,298 Research and development expenses 2,255,842 509,853 — 2,765,695 Selling, general and administrative expenses, excluding depreciation and amortization (1) — 19,342 8,789,728 8,809,070 Depreciation and amortization (2) — — 197,655 197,655 Loss from operations (3) (955,626 ) (414,113 ) (8,987,383 ) (10,357,122 ) Other expense (4) — — (1,061,190 ) (1,061,190 ) Income tax benefit 323,149 140,034 3,397,972 3,861,156 Net loss from continuing operations (632,477 ) (274,079 ) (6,650,601 ) (7,557,156 ) Loss from discontinued operations, net of tax (332,838 ) — — (332,838 ) Gain on sale of discontinued operations, net of tax 86,894,000 — — 86,894,000 Net income (loss) 85,928,685 (274,079 ) (6,650,601 ) 79,004,006 Total assets, net of depreciation and amortization: United States $ 14,675,489 $ 10,591 $ 7,835,426 $ 22,521,506 International 82,334 — 1,867 84,201 Capital expenditures — — 31,417 31,417

Note 1 - Summary of Significa_2

Note 1 - Summary of Significant Accounting Policies (Details Textual) - USD ($)	1 Months Ended	3 Months Ended	9 Months Ended
	Mar. 31, 2017	Mar. 31, 2018	Sep. 30, 2017	Dec. 31, 2019	Sep. 30, 2018	Jan. 01, 2018	Dec. 31, 2017
Notes Payable, Fair Value Disclosure					$ 2,200,000		$ 2,400,000
Notes Payable, Current, Total					2,164,330		2,353,639
Derivative Liability, Total					63,000		63,000
Deferred Revenue						$ 726,061
Cumulative Effect of New Accounting Principle in Period of Adoption							(700,000)
Accounting Standards Update 2014-09 [Member] | Sayre Pharmaceuticals [Member]
Deferred Revenue						700,000
Cumulative Effect of New Accounting Principle in Period of Adoption						$ 700,000
Accounting Standards Update 2016-18 [Member] | Fiscal Year 2016 [Member]
Prior Period Reclassification Adjustment		$ 5,000,000
Accounting Standards Update 2016-02 [Member] | Scenario, Forecast [Member]
Operating Lease, Right-of-Use Asset				$ 300,000
Operating Lease, Liability, Total				$ 300,000
Series NN Warrants [Member]
Class of Warrant or Right, Term	5 years
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 1.50
Series NN Warrants [Member] | Cardinal Health 414 [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	10,000,000
Class of Warrant or Right, Grants in Period, Estimated Fair Value			$ 3,300,000
Series NN Warrants [Member] | UCSD [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	1,000,000		1,000,000
Class of Warrant or Right, Grants in Period, Estimated Fair Value			$ 334,000
Former Executive [Member]
Accounts Payable, Disputed					$ 96,000		$ 96,000

Note 2 - Liquidity (Details Tex

Note 2 - Liquidity (Details Textual) - USD ($)	Sep. 13, 2018	Aug. 14, 2018	Dec. 31, 2017	Sep. 30, 2018	Mar. 03, 2017
Private Placement [Member]
Stock Issued During Period, Shares, New Issues	18,320,610			18,320,610
Stock Issued During Period, Value, New Issues	$ 3,000,000			$ 3,000,000
Former Chief Executive Officer and President [Member]
Severance Costs, Payable		$ 978,000
Severance Costs , Payable Period		2 years
Common Stock Shares Provided by Agreement		23,500,000
Severance Costs, Payable for Continuation of Healthcare Coverage		$ 35,000
Severance Costs, Payable, Period for Healthcare Coverage		1 year 120 days
PPCO [Member] | Platinum Loan Agreement [Member]
Convertible Debt, Total					$ 1,900,000
CRG Loan Agreement, Texas Case [Member] | Judicial Ruling [Member]
Loss Contingency, Damages Awarded, Value, Amount not Taken into Consideration			$ 4,100,000

Note 3 - Discontinued Operati_3

Note 3 - Discontinued Operations (Details Textual) - USD ($)	Apr. 02, 2018	Mar. 31, 2017	Mar. 03, 2017	Dec. 31, 2017	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Discontinued Operation, Gain (Loss) on Disposal of Discontinued Operation, Net of Tax, Total						$ 145,877	$ 43,053	$ 86,894,000
CRG Loan Agreement, Texas Case [Member] | Judicial Ruling [Member]
Loss Contingency, Damages Awarded, Value, Amount not Taken into Consideration				$ 4,100,000
CRG Loan Agreement, Texas Case [Member] | Judicial Ruling [Member] | Term Loan Agreement [Member]
Repayments of Debt		$ 59,000,000
Sale of Assets to Cardinal Health 414 [Member]
Sale of Assets, Cash Received from Buyer, After Adjustments, Inventory Transferred			$ 80,600,000
Sale of Assets, Cash Received from Buyer, After Adjustments, Advances of Guaranteed Earnout Payments			$ 3,000,000
Sale of Assets, Cash Received from Buyer as Result of Amendment	$ 6,000,000
Sale of Assets, Maximum Amount Receivable from Buyer for Unused Portion of Letter of Credit	$ 7,100,000
Discontinued Operation, Gain (Loss) on Disposal of Discontinued Operation, Net of Tax, Total							43,000	86,900,000
Discontinued Operation, Gain (Loss) on Disposal of Discontinued Operation, Net of Tax, Guaranteed Consideration							54,000	16,500,000
Warrants Issued During Period, Value Issued, Asset Sale								3,300,000
Sale of Assets, Legal and Other Fees Related to the Sale								2,000,000
Sale of Assets, Net Balance Sheet Dispositions and Write-offs						$ 800,000		800,000
Discontinued Operation, Tax Effect of Gain (Loss) from Disposal of Discontinued Operation							$ 11,000	$ 6,400,000

Note 3 - Discontinued Operati_4

Note 3 - Discontinued Operations - Discontinued Operations (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017	Dec. 31, 2017
Accrued liabilities					$ 7,092
Liabilities associated with discontinued operations, current					$ 7,092
Lymphoseek sales revenue				$ 2,917,213
Cost of goods sold				364,192
Gross profit				2,553,021
Operating expenses of discontinued operation:
Research and development		(5,951)	2,453	382,070
Selling, general and administrative				805,464
Total operating expenses		(5,951)	2,453	1,187,534
(Loss) income from discontinued operations		5,951	(2,453)	1,365,487
Interest expense				(1,718,506)
(Loss) income before income taxes		5,951	(2,453)	(353,019)
Benefit from (provision for) income taxes		(552)	515	20,181
(Loss) income from discontinued operations		$ 5,399	$ (1,938)	$ (332,838)

Note 4 - Revenue From Contrac_3

Note 4 - Revenue From Contracts With Customers (Details Textual) - USD ($)	3 Months Ended	9 Months Ended
	Sep. 30, 2018	Sep. 30, 2018	Jan. 01, 2018	Dec. 31, 2017
Cumulative Effect of New Accounting Principle in Period of Adoption				$ (700,000)
Revenue from Contract with Customer, Including Assessed Tax	$ 22,000	$ 287,000
Contract with Customer, Asset, Impairment Loss	0	$ 0
Contract with Customer, Payment Term, Minimum		15 days
Contract with Customer, Payment Term, Maximum		90 days
Contract with Customer, Asset, Net, Total	10,000	$ 10,000
Contract with Customer, Transaction Price of Royalties Using Expected Value Method	0	0
Capitalized Contract Cost, Net, Total	0	$ 0
INDIA
Contract with Customer, Term of Contract		8 years
CHINA
Contract with Customer, Term of Contract		10 years
Long-term Contract with Customer [Member]
Contract with Customer, Performance Obligation Satisfied in Previous Period	$ 0
Retained Earnings [Member]
Cumulative Effect of New Accounting Principle in Period of Adoption				$ (700,000)
Accounting Standards Update 2014-09 [Member] | Sayre Pharmaceuticals [Member]
Cumulative Effect of New Accounting Principle in Period of Adoption			$ 700,000
Accounting Standards Update 2014-09 [Member] | Retained Earnings [Member]
Cumulative Effect of New Accounting Principle in Period of Adoption			(700,000)
Accounting Standards Update 2014-09 [Member] | Retained Earnings [Member] | Sayre Pharmaceuticals [Member]
Cumulative Effect of New Accounting Principle in Period of Adoption			(100,000)
Accounting Standards Update 2014-09 [Member] | Retained Earnings [Member] | Beijing Sinotau Medical Research Co., Ltd. [Member]
Cumulative Effect of New Accounting Principle in Period of Adoption			$ (600,000)

Note 4 - Revenue From Contrac_4

Note 4 - Revenue From Contracts With Customers - Change in Deferred Revenue and Accumulated Deficit (Details) - USD ($)	Sep. 30, 2018	Jan. 01, 2018	Dec. 31, 2017
Deferred revenue		$ 726,061
Accumulated deficit	$ (333,562,563)	(320,608,968)	$ (319,908,968)
Calculated under Revenue Guidance in Effect before Topic 606 [Member]
Deferred revenue			26,061
Accumulated deficit			$ (319,908,968)
Difference between Revenue Guidance in Effect before and after Topic 606 [Member] | Accounting Standards Update 2014-09 [Member]
Deferred revenue		700,000
Accumulated deficit		$ (700,000)

Note 4 - Revenue From Contrac_5

Note 4 - Revenue From Contracts With Customers - Disaggregation of Revenue (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Revenue from contract with customer	$ 22,000		$ 287,000
Royalty [Member]
Revenue from contract with customer	2,382		9,842
Royalty [Member] | Diagnostics Segment [Member]
Revenue from contract with customer	2,382		9,842
Royalty [Member] | Therapeutics Segment [Member]
Revenue from contract with customer
NAV4694 Sublicense [Member]
Revenue from contract with customer	14,930		272,639
NAV4694 Sublicense [Member] | Diagnostics Segment [Member]
Revenue from contract with customer	14,930		272,639
NAV4694 Sublicense [Member] | Therapeutics Segment [Member]
Revenue from contract with customer
License [Member]
Revenue from contract with customer	19,930		277,639	100,000
License [Member] | Diagnostics Segment [Member]
Revenue from contract with customer	19,930		277,639	100,000
License [Member] | Therapeutics Segment [Member]
Revenue from contract with customer
Product and Service, Other [Member]
Revenue from contract with customer			15,037
Product and Service, Other [Member] | Diagnostics Segment [Member]
Revenue from contract with customer			15,037
Product and Service, Other [Member] | Therapeutics Segment [Member]
Revenue from contract with customer
Europe [Member] | Royalty [Member]
Revenue from contract with customer	2,382		9,842
Europe [Member] | Royalty [Member] | Diagnostics Segment [Member]
Revenue from contract with customer	2,382		9,842
Europe [Member] | Royalty [Member] | Therapeutics Segment [Member]
Revenue from contract with customer
INDIA | Royalty [Member]
Revenue from contract with customer
INDIA | Royalty [Member] | Diagnostics Segment [Member]
Revenue from contract with customer
INDIA | Royalty [Member] | Therapeutics Segment [Member]
Revenue from contract with customer
CHINA | Royalty [Member]
Revenue from contract with customer
CHINA | Royalty [Member] | Diagnostics Segment [Member]
Revenue from contract with customer
CHINA | Royalty [Member] | Therapeutics Segment [Member]
Revenue from contract with customer
CHINA | Expanded Tc99m Tilmanocept License Agreement [Member]
Revenue from contract with customer	5,000		5,000
CHINA | Expanded Tc99m Tilmanocept License Agreement [Member] | Diagnostics Segment [Member]
Revenue from contract with customer	5,000		5,000
CHINA | Expanded Tc99m Tilmanocept License Agreement [Member] | Therapeutics Segment [Member]
Revenue from contract with customer

Note 4 - Revenue From Contrac_6

Note 4 - Revenue From Contracts With Customers - Changes in Contract Liabilities (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Total deferred revenue, beginning of period	$ 721,024	$ 26,061	$ 26,061	$ 41,098
Impact of adoption of ASU 2014-09 and related standards			700,000
Revenue deferred related to sublicense			10,000
Revenue recognized from satisfaction of performance obligations	(5,000)		(20,037)	(15,037)
Total deferred revenue, end of period	$ 716,024	$ 26,061	$ 716,024	$ 26,061

Note 5 - Fair Value (Details Te

Note 5 - Fair Value (Details Textual) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017	Dec. 31, 2017
Derivative Liability, Total	$ 63,000		$ 63,000		$ 63,000
Fair Value, Inputs, Level 1 [Member]
Financial and Nonfinancial Liabilities, Fair Value Disclosure	0		0
Fair Value, Inputs, Level 3 [Member]
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease), Total	0	$ 0	0	$ 153,000
Fair Value, Inputs, Level 2 [Member]
Financial and Nonfinancial Liabilities, Fair Value Disclosure	0		0
Other Liabilities [Member]
Derivative Liability, Total	$ 63,000		$ 63,000		$ 63,000

Note 5 - Fair Value - Financial

Note 5 - Fair Value - Financial Liabilities Measured at Fair Value on a Recurring Basis (Details) - USD ($)		Sep. 30, 2018	Dec. 31, 2017
Derivative Liability, Total		$ 63,000	$ 63,000
Fair Value, Measurements, Recurring [Member]
Derivative Liability, Total	[1],[2]	63,000
Fair Value, Inputs, Level 1 [Member] | Fair Value, Measurements, Recurring [Member]
Derivative Liability, Total	[1],[2]
Fair Value, Inputs, Level 2 [Member] | Fair Value, Measurements, Recurring [Member]
Derivative Liability, Total	[1],[2]
Fair Value, Inputs, Level 3 [Member] | Fair Value, Measurements, Recurring [Member]
Derivative Liability, Total	[1],[2]	$ 63,000
[1]	a. Valuation Processes-Level 3 Measurements: The Company utilizes third-party valuation services that use complex models such as Monte Carlo simulation to estimate the value of our financial liabilities.
[2]	b. Sensitivity Analysis-Level 3 Measurements: Changes in the valuation of MT as a whole may cause material changes in the fair value of the MT warrants. Significant increases (decreases) in the valuation of MT, such as may be the result of additional financing, could result in a higher (lower) fair value measurement. A change in the valuation of MT would not necessarily result in a directionally similar change in the value of the MT warrants.

Note 6 - Stock-based Compensa_3

Note 6 - Stock-based Compensation (Details Textual) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Allocated Share-based Compensation Expense, Total	$ 44,000	$ 64,000	$ 261,000	$ 320,000
Employee Service Share-based Compensation, Tax Benefit from Compensation Expense	0	$ 0	0	$ 0
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Total	$ 101,000		$ 101,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition			1 year 73 days

Note 6 - Stock-based Compensa_4

Note 6 - Stock-based Compensation - Summary of Stock Option Activity (Details)	9 Months Ended
	Sep. 30, 2018USD ($)$ / sharesshares
Outstanding at beginning of period (in shares)	3,687,679
Outstanding at beginning of period (in dollars per share) | $ / shares	$ 1.50
Granted (in shares)	470,000
Granted, weighted average exercise price (in dollars per share) | $ / shares	$ 0.53
Exercised (in shares)
Canceled and Forfeited (in shares)	(116,000)
Canceled and Forfeited, weighted average exercise price (in dollars per share) | $ / shares	$ 0.71
Expired (in shares)	(7,000)
Expired (in dollars per share) | $ / shares	$ 0.66
Outstanding at end of period (in shares)	4,034,679
Outstanding at end of period (in dollars per share) | $ / shares	$ 1.41
Outstanding at end of period (Year)	6 years 109 days
Outstanding at end of period | $
Exercisable at end of period (in shares)	2,260,683
Exercisable at end of period (in dollars per share) | $ / shares	$ 2
Exercisable at end of period (Year)	4 years 109 days
Exercisable at end of period | $

Note 6 - Stock-based Compensa_5

Note 6 - Stock-based Compensation - Summary of Unvested Restricted Stock (Details) - Restricted Stock [Member]	9 Months Ended
	Sep. 30, 2018$ / sharesshares
Unvested at beginning of period (in shares) | shares	150,000
Unvested at beginning of period (in dollars per share) | $ / shares	$ 0.51
Granted (in shares) | shares	200,000
Granted, weighted average grant-date fair value (in dollars per share) | $ / shares	$ 0.37
Vested (in shares) | shares	(200,000)
Vested, weighted average grant-date fair value (in dollars per share) | $ / shares	$ 0.47
Forfeited (in shares) | shares	(50,000)
Forfeited, weighted average grant-date fair value (in dollars per share) | $ / shares	$ 0.36
Unvested at end of period (in shares) | shares	100,000
Unvested at end of period (in dollars per share) | $ / shares	$ 0.37

Note 7 - (Loss) Earnings Per _3

Note 7 - (Loss) Earnings Per Share (Details Textual) - shares	9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017
Stock Options, Warrants, Convertible Debt, and Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	18,600,000	15,100,000
Restricted Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	100,000	200,000

Note 7 - (Loss) Earnings Per _4

Note 7 - (Loss) Earnings Per Share - Earnings (Loss) Per Share (Details) - shares	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Weighted average shares outstanding, basic (in shares)	166,855,420	162,006,646	163,963,940	161,437,276
Dilutive shares related to warrants (in shares)				4,277,197
Unvested restricted stock (in shares)				200,000
Weighted average shares outstanding, diluted (in shares)	166,855,420	162,006,646	163,963,940	165,914,473

Note 8 - Accounts Payable, Ac_2

Note 8 - Accounts Payable, Accrued Liabilities and Other (Details Textual) - USD ($)	Sep. 30, 2018	Dec. 31, 2017
Executive Bonuses, Director Fees, Deferred Salary, and Scientific Advisory Board Fees [Member] | Accrued Liabilities and Other [Member]
Due to Related Parties, Current, Total	$ 2,300,000	$ 975,000
Former Executive [Member]
Accounts Payable, Disputed	$ 96,000	$ 96,000

Note 9 - Notes Payable (Details

Note 9 - Notes Payable (Details Textual) - USD ($)	Apr. 09, 2018	Mar. 26, 2018	Mar. 31, 2017	Mar. 03, 2017	Dec. 31, 2017	Nov. 30, 2017	Mar. 31, 2017	Dec. 31, 2016	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017	May 31, 2015	Jul. 31, 2012
Notes Payable, Current, Total					$ 2,353,639				$ 2,164,330		$ 2,164,330
Interest Expense, Debt, Total									45,000	$ 26,000	134,000	$ 91,000
Interest Expense Recorded Related to Amortization of Debt Discounts and Deferred Financing Costs									44,000	29,000	129,000	68,000
CRG [Member]
Draws on Letter of Credit	$ 7,100,000
Judicial Ruling [Member] | CRG Loan Agreement, Texas Case [Member]
Loss Contingency, Damages Awarded, Value, Additional Amount				$ 7,000,000	7,000,000
Loss Contingency, Damages Awarded, Value, Amount not Taken into Consideration					4,100,000
Judicial Ruling [Member] | CRG Loan Agreement, Texas Case [Member] | Maximum [Member]
Loss Contingency, Damages Awarded, Value				66,000,000	66,000,000
Platinum Loan Agreement [Member]
Interest Expense, Debt, Excluding Amortization											129,000	211,000
Reclassification of Interest Expense, Debt, Excluding Amortization, to Discontinued Operations												143,000
Convertible Debt, Fair Value Disclosures					2,000,000				2,200,000		2,200,000
Embedded Derivative, Fair Value of Embedded Derivative Liability					0				0		0
Term Loan Agreement [Member] | Judicial Ruling [Member] | CRG Loan Agreement, Texas Case [Member]
Repayments of Debt			$ 59,000,000
Notes Payable Issued for Prepayment of Insurance Premiums [Member]
Notes Payable, Current, Total					$ 318,000				0		0
Notes Payable Issued for Prepayment of Insurance Premiums [Member] | IPFS [Member]
Debt Instrument, Face Amount						$ 396,000		$ 348,000
Debt Instrument, Interest Rate, Stated Percentage						4.00%		8.99%
Debt Instrument, Term						300 days		240 days
Debt Instrument, Periodic Payment, Total						$ 40,000		$ 45,000
PPCO [Member] | Platinum Loan Agreement [Member]
Line of Credit Facility, Maximum Borrowing Capacity														$ 50,000,000
Repayments of Debt		$ 7,700,000
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease), Total									$ 0	$ 0	$ 0	$ (153,000)
CRG [Member] | Term Loan Agreement [Member] | Judicial Ruling [Member] | CRG Loan Agreement, Texas Case [Member]
Repayments of Debt				$ 59,000,000			$ 59,000,000
CRG [Member] | Term Loan Agreement [Member] | Term Loan [Member]
Long-term Debt, Total													$ 50,000,000

Note 10 - Terminated Lease Li_3

Note 10 - Terminated Lease Liability (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2017	Sep. 30, 2018	Jun. 01, 2017
Gain (Loss) on Contract Termination	$ (399,000)
Lease Termination of Blazer [Member]
Terminated Lease Liability	695,307	$ 604,402	$ 1,000,000
Lease Termination of Blazer [Member] | Selling, General and Administrative Expenses [Member]
Gain (Loss) on Disposition of Assets, Total	$ (706,000)

Note 10 - Terminated Lease Li_4

Note 10 - Terminated Lease Liability - Summary of Changes in Terminated Lease Liability (Details) - Lease Termination of Blazer [Member]	9 Months Ended
	Sep. 30, 2018USD ($)
Total liability, January 1, 2018	$ 695,307
Changes in estimated future payments	(43,393)
Payments under Blazer lease	(349,290)
Receipts from subtenant	273,869
Accretion of liability	27,909
Total liability, September 30, 2018	$ 604,402

Note 11 - Commitments and Con_2

Note 11 - Commitments and Contingencies (Details Textual) - USD ($)

Aug. 14, 2018

Apr. 12, 2018

Apr. 09, 2018

Mar. 26, 2018

Jan. 16, 2018

Nov. 02, 2017

Mar. 31, 2017

Mar. 03, 2017

Dec. 31, 2017

Mar. 31, 2017

Dec. 31, 2018

Sep. 30, 2018

Jun. 30, 2018

Stockholders' Equity Attributable to Parent, Ending Balance

$ 11,379,630

$ 1,341,696

$ 2,100,000

Common Stock, Par or Stated Value Per Share

$ 0.001

$ 0.001

Former Chief Executive Officer and President [Member]

Severance Costs, Payable

$ 978,000

Severance Costs , Payable Period

2 years

Severance Costs, Payable for Continuation of Healthcare Coverage

$ 35,000

Severance Costs, Payable, Period for Healthcare Coverage

1 year 120 days

Common Stock Shares Provided by Agreement

23,500,000

Former Chief Executive Officer and President [Member] | MT [Member] | Common Stock [Member] | Scenario, Forecast [Member]

Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners

5.00%

CRG [Member]

Draws on Letter of Credit

$ 7,100,000

CRG Loan Agreement, Texas Case [Member] | Judicial Ruling [Member]

Loss Contingency, Damages Awarded, Value, Additional Amount

$ 7,000,000

$ 7,000,000

Loss Contingency, Damages Awarded, Value, Amount not Taken into Consideration

4,100,000

CRG Loan Agreement, Texas Case [Member] | Judicial Ruling [Member] | Surety Bond [Member]

Loss Contingency, Amount Awarded to Other Party

$ 7,700,000

CRG Loan Agreement, Texas Case [Member] | Pending Litigation [Member]

Loss Contingency, Damages Awarded, Value, Amount not Taken into Consideration

$ 4,100,000

Loss Contingency, Damages Awarded,Value, Requested Modified Amount

$ 2,900,000

CRG Loan Agreement, Ohio Case [Member] | Pending Litigation [Member]

Loss Contingency, Damages Sought, Value

$ 4,100,000

Platinum-Montaur Life Sciences LLC Litigation [Member] | Pending Litigation [Member]

Loss Contingency, Damages Sought, Value

$ 1,900,000

Maximum [Member] | CRG Loan Agreement, Texas Case [Member] | Judicial Ruling [Member]

Loss Contingency, Damages Awarded, Value

66,000,000

$ 66,000,000

Term Loan Agreement [Member] | CRG Loan Agreement, Texas Case [Member] | Judicial Ruling [Member]

Repayments of Debt

$ 59,000,000

CRG [Member] | Term Loan Agreement [Member] | CRG Loan Agreement, Texas Case [Member] | Judicial Ruling [Member]

Repayments of Debt

59,000,000

$ 59,000,000

CRG [Member] | Term Loan Agreement [Member] | Maximum [Member]

Debt Instrument, Agreed-upon Final Payoff Amount

$ 66,000,000

Note 12 - Equity Instruments (D

Note 12 - Equity Instruments (Details Textual) - USD ($)	Sep. 13, 2018	Sep. 30, 2018	Sep. 30, 2017	Dec. 31, 2017
Common Stock, Par or Stated Value Per Share		$ 0.001		$ 0.001
Stock Issued During Period, Shares, Employee Benefit Plan		94,684	105,308
Issuance of Stock to Defined Contribution Plan for Employer Matching Contribution		$ 35,980	$ 53,707
Common Stock [Member]
Stock Issued During Period, Shares, Employee Benefit Plan		94,684
Employees [Member] | Common Stock [Member]
Stock Issued During Period, Shares, Issued for Services		1,118,760	710,353
Stock Issued During Period, Value, Issued for Services		$ 317,000	$ 369,000
Director [Member] | Common Stock [Member]
Stock Issued During Period, Shares, Issued for Services		0	16,406
Stock Issued During Period, Value, Issued for Services			$ 10,500
Private Placement [Member]
Stock Issued During Period, Shares, New Issues	18,320,610	18,320,610
Common Stock, Par or Stated Value Per Share		$ 0.001
Stock Issued During Period, Value, New Issues	$ 3,000,000	$ 3,000,000
Private Placement [Member] | Common Stock [Member]
Stock Issued During Period, Shares, New Issues		18,320,610
Stock Issued During Period, Value, New Issues		$ 18,321

Note 13 - Stock Warrants (Detai

Note 13 - Stock Warrants (Details Textual) - USD ($)	1 Months Ended		9 Months Ended
	Mar. 31, 2017	Jan. 31, 2017	Sep. 30, 2018	Sep. 30, 2017
Series NN Warrants [Member]
Class of Warrant or Right, Term	5 years
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 1.50
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate	77.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate	2.00%
Series NN Warrants [Member] | Cardinal Health 414 [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	10,000,000
Class of Warrant or Right, Grants in Period, Estimated Fair Value				$ 3,300,000
Series NN Warrants [Member] | UCSD [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	1,000,000			1,000,000
Class of Warrant or Right, Grants in Period, Estimated Fair Value				$ 334,000
Warrants to Purchase Navidea Common Stock [Member]
Class of Warrant or Right, Outstanding			16,400,000
Warrants to Purchase Navidea Common Stock [Member] | Minimum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights			$ 0.01
Class of Warrant or Right, Outstanding Term			1 year
Warrants to Purchase Navidea Common Stock [Member] | Maximum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights			$ 2.50
Class of Warrant or Right, Outstanding Term			17 years
Warrants to Purchase Navidea Common Stock [Member] | Weighted Average [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights			$ 1.15
Warrants to Purchase MT Common Stock [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights			$ 2,000
Class of Warrant or Right, Outstanding			300
Chief Executive Officer [Member]
Class of Warrant or Right, Exercises in Period		5,411,850
Stock Issued During Period, Shares, Issued for Exercise of Warrants		5,411,850
Proceeds from Warrant Exercises		$ 54,119

Note 14 - Income Taxes (Details

Note 14 - Income Taxes (Details Textual) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017	Dec. 31, 2017
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent			21.00%		35.00%
Tax rate, Sequestration Reduction			6.20%
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount			$ 76,000
Unrecognized Tax Benefits, Ending Balance	$ 0		0		$ 0
Income Tax Expense (Benefit), Total	$ 76,259	$ (775,750)	65,330	$ (3,861,156)
Effective Income Tax Rate Reconciliation, Percent, Total	2.00%	34.00%
Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member]
Operating Loss Carryforwards, Total	$ 131,800,000		131,800,000
Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member] | Research Tax Credit Carryforward [Member]
Tax Credit Carryforward, Amount	9,700,000		9,700,000
State and Local Jurisdiction [Member]
Operating Loss Carryforwards, Total	20,400,000		$ 20,400,000
Earliest Tax Year [Member]
Open Tax Year			2,014
Latest Tax Year [Member]
Open Tax Year			2,017
Other Noncurrent Liabilities [Member]
Deferred Tax Assets, Tax Credit Carryforwards, Alternative Minimum Tax	$ 1,100,000		$ 1,100,000
Other Noncurrent Assets [Member]
Deferred Tax Assets, Tax Credit Carryforwards, Alternative Minimum Tax					$ 1,200,000

Note 15 - Segments (Details Tex

Note 15 - Segments (Details Textual)		3 Months Ended		9 Months Ended
		Sep. 30, 2018USD ($)	Sep. 30, 2017USD ($)	Sep. 30, 2018USD ($)	Sep. 30, 2017USD ($)
Revenues, Total		$ 231,458	$ 223,669	$ 1,050,030	$ 1,415,298
Number of Primary Types of Products Sold		2		2
Depreciation, Depletion and Amortization, Nonproduction, Total	[1]	$ 37,590	50,326	$ 113,088	197,655
Selling, General and Administrative Expenses [Member]
Depreciation, Depletion and Amortization, Nonproduction, Total		$ 37,590	$ 50,326	113,088	$ 197,655
Intersegment Eliminations [Member]
Revenues, Total				$ 0
[1]	Depreciation and amortization is reflected in selling, general and administrative expenses ($37,590 and $50,326 for the three-month periods ended September 30, 2018 and 2017, and $113,088 and $197,655 for the nine-month periods ended September 30, 2018 and 2017, respectively).

Note 15 - Segments - Segment In

Note 15 - Segments - Segment Information (Details) - USD ($)		3 Months Ended			9 Months Ended
		Sep. 30, 2018		Sep. 30, 2017	Sep. 30, 2018		Sep. 30, 2017		Dec. 31, 2017
Revenue from contract with customer		$ 22,000			$ 287,000
Grant and other revenue		209,146		$ 223,669	762,549		$ 1,315,298
Revenue		231,458		223,669	1,050,030		1,415,298
Cost of revenue		38,101			73,811
Research and development expenses		1,225,770		874,547	3,367,444		2,765,695
Selling, general and administrative expenses, excluding depreciation and amortization	[1]	2,651,113		1,684,381	6,141,386		8,809,070
Depreciation, Depletion and Amortization, Nonproduction, Total	[2]	37,590		50,326	113,088		197,655
Loss from operations		(3,721,116)	[3]	(2,385,585)	(8,645,699)	[3]	(10,357,122)	[3]
Other expense		(24,534)	[4]	69,071	(4,284,014)	[4]	(1,061,190)	[4]
Income tax expense		(76,259)		775,750	(65,330)		3,861,156
Net loss from continuing operations		(3,821,909)		(1,540,764)	(12,995,043)		(7,557,156)
Net income (loss)		(3,821,909)		(1,389,488)	(12,953,928)		79,004,006
Total assets, net of depreciation and amortization		9,109,042			9,109,042				$ 20,781,436
Capital expenditures		16,152		23,247	19,317		31,417
Other income		(24,534)	[4]	69,071	(4,284,014)	[4]	(1,061,190)	[4]
(Loss) income from discontinued operations				5,399	(1,938)		(332,838)
Gain on sale of discontinued operations, net of tax				145,877	43,053		86,894,000
Net loss		(3,821,909)		(1,389,488)	(12,953,928)		79,004,006
UNITED STATES
Total assets, net of depreciation and amortization		9,089,645		22,521,506	9,089,645		22,521,506
Non-US [Member]
Total assets, net of depreciation and amortization		19,397		84,201	19,397		84,201
Royalty [Member]
Revenue from contract with customer		2,382			9,842
License [Member]
Revenue from contract with customer		19,930			277,639		100,000
Diagnostics Segment [Member]
Grant and other revenue		65,505		210,479	454,830		1,200,216
Revenue		87,817			742,311		1,300,216
Cost of revenue		38,101			73,811
Research and development expenses		711,355		734,539	2,409,524		2,255,842
Selling, general and administrative expenses, excluding depreciation and amortization	[1]
Depreciation, Depletion and Amortization, Nonproduction, Total	[2]
Loss from operations		(661,639)	[3]	(524,060)	(1,741,024)	[3]	(955,626)	[3]
Other expense			[4]			[4]		[4]
Income tax expense		(10,081)		175,496	(8,797)		323,149
Net loss from continuing operations		(671,720)		(348,564)	(1,749,821)		(632,477)
Net income (loss)		(671,720)		(197,288)	(1,708,706)		85,928,685
Capital expenditures
Other income			[4]			[4]		[4]
(Loss) income from discontinued operations				5,399	(1,938)		(332,838)
Gain on sale of discontinued operations, net of tax				145,877	43,053		86,894,000
Net loss		(671,720)		(197,288)	(1,708,706)		85,928,685
Diagnostics Segment [Member] | UNITED STATES
Total assets, net of depreciation and amortization		117,722		14,675,489	117,722		14,675,489
Diagnostics Segment [Member] | Non-US [Member]
Total assets, net of depreciation and amortization		18,239		82,334	18,239		82,334
Diagnostics Segment [Member] | Royalty [Member]
Revenue from contract with customer		2,382			9,842
Diagnostics Segment [Member] | License [Member]
Revenue from contract with customer		19,930			277,639		100,000
Therapeutics Segment [Member]
Grant and other revenue		143,641		13,190	307,719		115,082
Revenue		143,641			307,719		115,082
Cost of revenue
Research and development expenses		514,415		140,008	957,920		509,853
Selling, general and administrative expenses, excluding depreciation and amortization	[1]	20,532		13,359	45,769		19,342
Depreciation, Depletion and Amortization, Nonproduction, Total	[2]
Loss from operations		(391,306)	[3]	(140,177)	(695,970)	[3]	(414,113)	[3]
Other expense			[4]			[4]		[4]
Income tax expense		(3,879)		46,942	(3,517)		140,034
Net loss from continuing operations		(395,185)		(93,235)	(699,487)		(274,079)
Net income (loss)		(395,185)		(93,235)	(699,487)		(274,079)
Capital expenditures
Other income			[4]			[4]		[4]
(Loss) income from discontinued operations
Gain on sale of discontinued operations, net of tax
Net loss		(395,185)		(93,235)	(699,487)		(274,079)
Therapeutics Segment [Member] | UNITED STATES
Total assets, net of depreciation and amortization		72,622		10,591	72,622		10,591
Therapeutics Segment [Member] | Non-US [Member]
Total assets, net of depreciation and amortization
Therapeutics Segment [Member] | Royalty [Member]
Revenue from contract with customer
Therapeutics Segment [Member] | License [Member]
Revenue from contract with customer
Corporate Segment [Member]
Grant and other revenue
Revenue
Cost of revenue
Research and development expenses
Selling, general and administrative expenses, excluding depreciation and amortization	[1]	2,630,581		1,671,022	6,095,617		8,789,728
Depreciation, Depletion and Amortization, Nonproduction, Total	[2]	37,590		50,326	113,088		197,655
Loss from operations		(2,668,171)	[3]	(1,721,348)	(6,208,705)	[3]	(8,987,383)	[3]
Other expense		(24,534)	[4]	69,071	(4,284,014)	[4]	(1,061,190)	[4]
Income tax expense		(62,299)		553,312	(53,017)		3,397,972
Net loss from continuing operations		(2,755,004)		(1,098,965)	(10,545,736)		(6,650,601)
Net income (loss)		(2,755,004)		(1,098,965)	(10,545,736)		(6,650,601)
Capital expenditures		16,152		23,247	19,317		31,417
Other income		(24,534)	[4]	69,071	(4,284,014)	[4]	(1,061,190)	[4]
(Loss) income from discontinued operations
Gain on sale of discontinued operations, net of tax
Net loss		(2,755,004)		(1,098,965)	(10,545,736)		(6,650,601)
Corporate Segment [Member] | UNITED STATES
Total assets, net of depreciation and amortization		8,899,301		7,835,426	8,899,301		7,835,426
Corporate Segment [Member] | Non-US [Member]
Total assets, net of depreciation and amortization		1,158		$ 1,867	1,158		1,867
Corporate Segment [Member] | Royalty [Member]
Revenue from contract with customer
Corporate Segment [Member] | License [Member]
Revenue from contract with customer
[1]	General and administrative expenses, excluding depreciation and amortization, represent costs that relate to the general administration of the Company and as such are not currently allocated to our individual reportable segments.
[2]	Depreciation and amortization is reflected in selling, general and administrative expenses ($37,590 and $50,326 for the three-month periods ended September 30, 2018 and 2017, and $113,088 and $197,655 for the nine-month periods ended September 30, 2018 and 2017, respectively).
[3]	Income (loss) from operations does not reflect the allocation of certain selling, general and administrative expenses, excluding depreciation and amortization, to our individual reportable segments, other than those expenses directly incurred by MT.
[4]	Amounts consist primarily of losses on debt extinguishment and changes in fair value of financial instruments, which are not currently allocated to our individual reportable segments.

Note 16 - Supplemental Disclo_2

Note 16 - Supplemental Disclosure for Statements of Cash Flows (Details Textual) - USD ($)	9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Mar. 31, 2017
Interest Paid, Excluding Capitalized Interest, Operating Activities	$ 8,000	$ 7,400,000
Stock Issued During Period, Shares, Employee Benefit Plan	94,684	105,308
Issuance of Stock to Defined Contribution Plan for Employer Matching Contribution	$ 35,980	$ 53,707
Series NN Warrants [Member] | UCSD [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		1,000,000	1,000,000
Class of Warrant or Right, Grants in Period, Estimated Fair Value		$ 334,000